<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02532738</url>
  </required_header>
  <id_info>
    <org_study_id>MSCINRCD</org_study_id>
    <nct_id>NCT02532738</nct_id>
  </id_info>
  <brief_title>The Efficiency of MSC in Refractory Crohn's Disease</brief_title>
  <official_title>A Stage II Clinical Trial Comparing the Efficiacy of Routine Treatment Combined With or Without MSC Therapy in Refractory Crohn's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sixth Affiliated Hospital, Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Third Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sixth Affiliated Hospital, Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators' preliminary study indicates that MSC is effective therapy in treating IBD.
      But the standard treatment is still lacking and the effect is not stable in IBD patients.
      This study is to explore the efficacy and standard strategy when using MSC in refractory IBD.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Response of CD patients 12 weeks after receiving treatment (Reduction of CDAI score at less 100)</measure>
    <time_frame>12 weeks after receiving treatment</time_frame>
    <description>Reduction of CDAI score at less 100</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Response of CD patients 6 weeks after receiving treatment (CDAI score less than 150)</measure>
    <time_frame>6 weeks after receiving treatment</time_frame>
    <description>CDAI score less than 150</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">3</enrollment>
  <condition>Crohn's Disease</condition>
  <arm_group>
    <arm_group_label>MSC-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this arms receive routine treatment with 3×10E6/kg of MSC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MSC-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this arms receive routine treatment with 6×10E6/kg of MSC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ctrl</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients in this arms receive routine treatment with NS injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Routine Treatment of CD</intervention_name>
    <description>The Drug including 6MP, AZA, infliximab and thalidomide</description>
    <arm_group_label>MSC-1</arm_group_label>
    <arm_group_label>MSC-2</arm_group_label>
    <arm_group_label>Ctrl</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MSC treatment 01</intervention_name>
    <description>Injection of 3×10E6/kg of MSC</description>
    <arm_group_label>MSC-1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MSC treatment 02</intervention_name>
    <description>Injection of 6×10E6/kg of MSC</description>
    <arm_group_label>MSC-2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>NS</intervention_name>
    <description>Injection of NS</description>
    <arm_group_label>Ctrl</arm_group_label>
    <other_name>normal saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Failure or intolerance to GC, immune inhibitors and biological agents treatment

          -  CDAI between 250-450

          -  Weight between 40-150 kg

          -  Normal renal function

          -  endoscopic or imaging diagnosis of CD in the small intestine, colon ileocolon

          -  Signed informed consent

        Exclusion Criteria:

          -  HIV or active hepatitis patients;

          -  Allergic to CT contrast agents, cattle or pig products;

          -  Stricture or perforation type CD;

          -  Recieved permanent colostomy;

          -  Used biological preparation in 3 months

          -  Used prednisone &gt; 20 mg/day within 1 month ;

          -  Patients with short bowel syndrome;

          -  Need total parenteral nutrition;

          -  Liver meritorious service is abnormal;

          -  Suffering from malignant tumor during the last 5 years;

          -  Combined bacterial or viral enteritis;

          -  Suffering from intestinal typicality thickening of the living

          -  Patients with tuberculosis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 23, 2015</study_first_submitted>
  <study_first_submitted_qc>August 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2015</study_first_posted>
  <last_update_submitted>August 25, 2015</last_update_submitted>
  <last_update_submitted_qc>August 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>efficacy of MSC</keyword>
  <keyword>refractory</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

